查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602272

mRNA 平台市場：按 mRNA 類型、mRNA 分子、應用、適應症和最終用戶分類 - 2025-2030 年全球預測

mRNA Platform Market by mRNA Type (Nucleoside-Modified mRNA, Unmodified mRNA), mRNA Molecule (Monocistronic mRNA, Polycistronic mRNA), Application, Indication, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年mRNA平台市場估值為135.2億美元，預計2024年將達到163.3億美元，複合年成長率為21.44%，到2030年將達到527.1億美元。

mRNA 平台是生物技術和醫學領域的一個變革性領域，主要涉及傳訊RNA(mRNA) 技術的開發及其在治療和疫苗中的應用。最近 mRNA COVID-19 疫苗的快速開發和部署凸顯了它們的需求，並證明了加速疫苗生產的能力。除了疫苗之外，mRNA的應用範圍正在擴展到個人化醫療、蛋白質替代療法以及癌症和遺傳性疾病等疾病的治療。最終用途行業主要包括從事研發和治療開發的製藥公司、生物技術公司和醫療保健提供者。市場成長的主要驅動力是技術進步、解決未滿足的醫療需求的能力以及增加對生物技術的投資。新的商機包括探索 mRNA 的非傳統應用，例如再生醫學和慢性病管理，以及擴大 mRNA 在人類醫學之外的使用案例，例如獸醫應用。為了利用這些機會，相關人員應該投資於研究夥伴關係和創新，以降低生產成本並增強交付解決方案。

主要市場統計
基準年[2023] 135.2億美元
預計年份 [2024] 163.3億美元
預測年份 [2030] 527.1億美元
複合年成長率（%） 21.44%

然而，該市場面臨著監管障礙、高開發成本、儲存和運輸 mRNA 的後勤複雜性以及現有治療方法的競爭等挑戰。知識產權壁壘和供應鏈脆弱性也是主要限制因素。然而，技術創新的潛力是巨大的，特別是在提高 mRNA 製劑的穩定性、開發脂質奈米粒子等新型遞送系統以及最佳化大規模製造技術方面。這些發展有可能重新定義疾病管理和治療。市場高度活躍，特點是技術變化迅速、商業性興趣高、研發活動廣泛。為了實現永續成長，公司應專注於加速研究和簡化監管流程的協作生態系統，並為基於 mRNA 的新創新提供更順暢的市場路徑，並與政策制定者合作。

市場動態：揭示快速發展的 mRNA 平台市場的關鍵市場洞察

供需的動態交互作用正在改變 mRNA 平台市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 擴大疫苗開發以滿足不斷成長的全球衛生準備需求
    • 隨著生物醫學領域的進步，mRNA 療法和疫苗的可用性增加生物技術突破將 mRNA 療法和疫苗的速度和擴充性推向新的高度
    • 增加資金籌措以推動 mRNA 療法和醫療保健進步的突破
    • 由於慢性病的增加，對 mRNA 治療的需求不斷增加
  • 市場限制因素
    • 高製造成本限制了基於 mRNA 的治療方法的採用和擴充性
    • 監管障礙和漫長的核准流程減緩了 mRNA 平台的開發和市場進入
  • 市場機會
    • 透過整合 mRNA 平台進行精準治療，轉型個人化醫療
    • 擴大 mRNA 技術在疫苗以外的治療領域的潛力
    • 透過與製藥公司的強大合作，快速加速基於 mRNA 的治療方法的開發和商業化
  • 市場挑戰
    • 用於儲存和分發基於 mRNA 的治療藥物的低溫運輸基礎設施有限；
    • mRNA 療法的接受度和廣泛使用有潛在的安全性和免疫抗原性問題。

波特五力：駕馭 mRNA 平台市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解 mRNA 平台市場的外部影響

外部宏觀環境因素在塑造 mRNA 平台市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解mRNA平台市場的競爭狀況

對 mRNA 平台市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV定位矩陣mRNA平台市場廠商績效評估

FPNV 定位矩陣是評估 mRNA 平台市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製 mRNA 平台市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對 mRNA 平台市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 疫苗開發不斷進步，以滿足全球衛生措施日益成長的需求
      • 隨著生物醫學領域的進步，mRNA 治療和疫苗的可用性正在增加。

生物技術的進步使 mRNA 療法和疫苗在速度和擴充性達到新的高度

      • 增加資金以加速 mRNA 治療和醫療保健進步的突破
      • 隨著慢性病的增加，對mRNA治療的需求不斷增加
    • 抑制因素
      • 高生產成本限制了基於 mRNA 的藥物的採用和擴充性
      • 監管障礙和漫長的核准流程減緩了 mRNA 平台的開發和市場進入
    • 機會
      • 整合 mRNA 平台將個人化醫療轉變為精準治療
      • 擴大 mRNA 技術在疫苗以外的治療領域的潛力
      • 與製藥公司的強力合作迅速加速了基於 mRNA 的治療方法的開發和商業化
    • 任務
      • 用於儲存和分發基於 mRNA 的療法的低溫運輸基礎設施有限
      • 接受和廣泛使用 mRNA 療法的潛在安全性和免疫抗原性問題
  • 市場區隔分析
    • mRNA類型：核苷修飾的mRNA能夠平衡免疫反應的有效性並減少副作用，並提高穩定性。
    • mRNA分子：單順反子mRNA是開發精準標靶治療所必需的
    • 應用：透過新型 mRNA 平台快速有效生產疫苗的需求不斷擴大
    • 適應症：全球癌症發生率正在上升
    • 最終用戶：製藥公司廣泛參與 mRNA 平台的行銷和許可
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第 6 章 mRNA 平台市場（依 mRNA 類型）

  • 核苷修飾的mRNA
  • 未修飾的mRNA

第 7 章 mRNA 分子的 mRNA 平台市場

  • 單順反子mRNA
  • 多順反子mRNA

第8章 mRNA 平台市場：依應用分類

  • 藥物
  • 疫苗

第 9 章 mRNA 平台市場（按適應症）

  • 自體免疫疾病
  • 癌症
  • 感染疾病
  • 呼吸系統疾病

第 10 章 mRNA 平台市場：依最終用戶分類

  • 醫院/診所
  • 製藥公司
  • 研究/學術機構

第11章美洲mRNA平台市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太mRNA平台市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲/中東/非洲mRNA平台市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Cipla 加強對 Esrys 的投資，以加速新興市場基於 mRNA 的呼吸療法
    • Arcturus Therapeutics 在歐洲大會上展示了吸入 mRNA 治療囊腫纖維化的有希望的初步資料
    • 默克投資超過 3 億歐元新建研究中心，致力於 mRNA 和抗體開發
    • CureVac 和 MD 安德森合作開發基於 mRNA 的癌症疫苗，以滿足未滿足的醫療需求
    • VBI Vaccines Inc. 在加拿大政府的支持下推動 mRNA 疫苗技術
    • Blackstone 承諾提供 7.5 億美元支持 Moderna 流感疫苗的開發和商業化
    • Novo Holdings以165億美元收購Catalent，並計劃將戰略地點出售給諾和諾德
    • TriLink BioTechnologies 與FUJIFILM Toyama Chemical 合作提高 mRNA 藥物開發和製造的效率
    • Eslis 開始首次針對病毒引起的氣喘的創新吸入 RNA 療法的人體試驗
    • Moderna 透過新的澳洲培養箱網路和疫苗生產設施來推進 mRNA 研究
    • 比爾及梅琳達蓋茲基金會投資 4,000 萬美元為低收入國家生產低成本 mRNA 疫苗
    • 默克和 Moderna 開始治療進行性黑色素瘤的國際 3 期試驗
    • Applied DNA Sciences 收購 Spindle Biotech 以加強 mRNA 生產，旨在提高產量並降低成本
    • Sensible Biotechnologies 與 Gingo Bioworks 結成策略夥伴關係，以徹底改變 mRNA 生產
  • 戰略分析和建議
    • 輝瑞公司
    • 摩德納公司
    • 賽諾菲公司
    • 易特瑞斯有限公司

公司名單

  • Acuitas Therapeutics Inc.
  • Arcturus Therapeutics Holdings, Inc.
  • Beam Therapeutics Inc.
  • BioNTech SE
  • Catalent, Inc.
  • CureVac NV
  • Daiichi Sankyo Company, Limited
  • Danaher Corporation
  • eTheRNA Immunotherapies NV
  • Ethris GmbH
  • FUJIFILM Holdings Corporation
  • Gritstone bio, Inc.
  • In-Cell-Art
  • Merck KGaA
  • Moderna Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Precision BioSciences, Inc.
  • Regulus Therapeutics Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Takara Bio Inc.
  • Telesis Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Tiba Biotech LLC
  • TriLink BioTechnologies by Maravai LifeSciences
  • Verve Therapeutics, Inc.
Product Code: MRR-374DB5A05ED7

The mRNA Platform Market was valued at USD 13.52 billion in 2023, expected to reach USD 16.33 billion in 2024, and is projected to grow at a CAGR of 21.44%, to USD 52.71 billion by 2030.

The mRNA platform is a transformative segment within biotechnology and pharmaceuticals, involving the development of messenger RNA (mRNA) technologies for applications primarily in therapeutics and vaccines. Its necessity has been underscored recently by the rapid development and deployment of mRNA COVID-19 vaccines, showcasing its ability to accelerate vaccine production. Beyond vaccines, mRNA's application scope extends to personalized medicine, protein replacement therapies, and treatment of diseases such as cancer and genetic disorders. End-use industries predominantly include pharmaceuticals, biotech firms, and healthcare providers engaged in research and therapeutic development. Market growth is primarily driven by technological advancements, the ability to address unmet medical needs, and increasing investment in biotech. Emerging opportunities include exploring mRNA for non-traditional uses like regenerative medicine and chronic disease management, and expanding mRNA use cases outside of human medicine, such as in veterinary applications. To capitalize on these opportunities, stakeholders should invest in research partnerships and technological innovations that reduce production costs and enhance delivery solutions.

KEY MARKET STATISTICS
Base Year [2023] USD 13.52 billion
Estimated Year [2024] USD 16.33 billion
Forecast Year [2030] USD 52.71 billion
CAGR (%) 21.44%

However, the market faces challenges such as regulatory hurdles, high developmental costs, and logistical complexities in mRNA storage and transport, alongside competition from established therapeutic modalities. Intellectual property barriers and supply chain vulnerabilities also pose significant limitations. Nonetheless, the potential for innovation is immense, particularly in improving the stability of mRNA products, developing novel delivery systems (like lipid nanoparticles), and optimizing large-scale manufacturing techniques. These developments could redefine disease management and treatment modalities. The market is highly dynamic, characterized by rapid technological shifts, considerable commercial interest, and extensive R&D activities. For sustained growth, companies should focus on collaborative ecosystems that expedite research and streamline regulatory processes, and they should engage with policy makers to facilitate smoother pathways to market for new mRNA-based innovations.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving mRNA Platform Market

The mRNA Platform Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing development of vaccines to meet the rising need for global health preparedness
    • Rising availability of mRNA treatments and vaccines with increasing advancements in the biomedical field Biotech Breakthroughs Propel mRNA Treatments and Vaccines to New Heights in Speed and Scalability
    • Increased funding to fuel breakthroughs in mRNA therapeutics and healthcare advancements
    • Growing need for mRNA therapy with the rising prevalence of chronic diseases
  • Market Restraints
    • High production costs limiting the widespread adoption and scalability of mRNA-based medical treatments
    • Regulatory hurdles and lengthy approval processes slowing down mRNA platform development and market entry
  • Market Opportunities
    • Integration of mRNA platforms to transform personalized medicine with precision therapies
    • Growing potential of mRNA technology in non-vaccine therapeutic areas
    • Rapid acceleration for the development and commercialization of mRNA-based therapies through robust collaborations with pharmaceutical companies
  • Market Challenges
    • Limited cold chain infrastructure for storing and distributing mRNA-based treatments
    • Potential safety and immunogenicity concerns for acceptance and widespread use of mRNA therapies

Porter's Five Forces: A Strategic Tool for Navigating the mRNA Platform Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the mRNA Platform Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the mRNA Platform Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the mRNA Platform Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the mRNA Platform Market

A detailed market share analysis in the mRNA Platform Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the mRNA Platform Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the mRNA Platform Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the mRNA Platform Market

A strategic analysis of the mRNA Platform Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the mRNA Platform Market, highlighting leading vendors and their innovative profiles. These include Acuitas Therapeutics Inc., Arcturus Therapeutics Holdings, Inc., Beam Therapeutics Inc., BioNTech SE, Catalent, Inc., CureVac N.V., Daiichi Sankyo Company, Limited, Danaher Corporation, eTheRNA Immunotherapies NV, Ethris GmbH, FUJIFILM Holdings Corporation, Gritstone bio, Inc., In-Cell-Art, Merck KGaA, Moderna Inc., Novo Nordisk A/S, Pfizer Inc., Precision BioSciences, Inc., Regulus Therapeutics Inc., Sangamo Therapeutics, Inc., Sanofi SA, Takara Bio Inc., Telesis Bio Inc., Thermo Fisher Scientific Inc., Tiba Biotech LLC, TriLink BioTechnologies by Maravai LifeSciences, and Verve Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the mRNA Platform Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on mRNA Type, market is studied across Nucleoside-Modified mRNA and Unmodified mRNA.
  • Based on mRNA Molecule, market is studied across Monocistronic mRNA and Polycistronic mRNA.
  • Based on Application, market is studied across Drugs and Vaccines.
  • Based on Indication, market is studied across Autoimmune Diseases, Cancer, Infectious Diseases, and Respiratory Diseases.
  • Based on End-User, market is studied across Hospitals & Clinics, Pharmaceutical Companies, and Research & Academic Institutiions.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing development of vaccines to meet the rising need for global health preparedness
      • 5.1.1.2. Rising availability of mRNA treatments and vaccines with increasing advancements in the biomedical field

Biotech Breakthroughs Propel mRNA Treatments and Vaccines to New Heights in Speed and Scalability

      • 5.1.1.3. Increased funding to fuel breakthroughs in mRNA therapeutics and healthcare advancements
      • 5.1.1.4. Growing need for mRNA therapy with the rising prevalence of chronic diseases
    • 5.1.2. Restraints
      • 5.1.2.1. High production costs limiting the widespread adoption and scalability of mRNA-based medical treatments
      • 5.1.2.2. Regulatory hurdles and lengthy approval processes slowing down mRNA platform development and market entry
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of mRNA platforms to transform personalized medicine with precision therapies
      • 5.1.3.2. Growing potential of mRNA technology in non-vaccine therapeutic areas
      • 5.1.3.3. Rapid acceleration for the development and commercialization of mRNA-based therapies through robust collaborations with pharmaceutical companies
    • 5.1.4. Challenges
      • 5.1.4.1. Limited cold chain infrastructure for storing and distributing mRNA-based treatments
      • 5.1.4.2. Potential safety and immunogenicity concerns for acceptance and widespread use of mRNA therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. mRNA Type: Ability of nucleoside-modified mRNA to balance immune response efficacy with reduced side effects and offer enhanced stability
    • 5.2.2. mRNA Molecule: Requirement of monocistronic mRNA for the development of precise, targeted therapies
    • 5.2.3. Application: Expanding need for quick and effective production of vaccines through novel mRNA platforms
    • 5.2.4. Indication: Increasing prevalence of cancer cases worldwide
    • 5.2.5. End-User: Extensive involvement of pharmaceutical companies in the marketing and authorization of mRNA platforms
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. mRNA Platform Market, by mRNA Type

  • 6.1. Introduction
  • 6.2. Nucleoside-Modified mRNA
  • 6.3. Unmodified mRNA

7. mRNA Platform Market, by mRNA Molecule

  • 7.1. Introduction
  • 7.2. Monocistronic mRNA
  • 7.3. Polycistronic mRNA

8. mRNA Platform Market, by Application

  • 8.1. Introduction
  • 8.2. Drugs
  • 8.3. Vaccines

9. mRNA Platform Market, by Indication

  • 9.1. Introduction
  • 9.2. Autoimmune Diseases
  • 9.3. Cancer
  • 9.4. Infectious Diseases
  • 9.5. Respiratory Diseases

10. mRNA Platform Market, by End-User

  • 10.1. Introduction
  • 10.2. Hospitals & Clinics
  • 10.3. Pharmaceutical Companies
  • 10.4. Research & Academic Institutiions

11. Americas mRNA Platform Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific mRNA Platform Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa mRNA Platform Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Cipla Boosts Investment in Ethris to Accelerate mRNA-Based Respiratory Therapies for Emerging Markets
    • 14.3.2. Arcturus Therapeutics to Present Promising Early Data on Inhaled mRNA Treatment for Cystic Fibrosis at European Conference
    • 14.3.3. Merck Invests Over Euro 300 Million in New Research Center Focused on mRNA and Antibody Development
    • 14.3.4. CureVac and MD Anderson Collaborate on mRNA-Based Cancer Vaccines for Unmet Medical Needs
    • 14.3.5. VBI Vaccines Inc.'s Advancement in mRNA Vaccine Technology with Government of Canada Support
    • 14.3.6. Blackstone Commits USD 750 Million to Support Moderna's Influenza Vaccine Development and Commercialization
    • 14.3.7. Novo Holdings Acquires Catalent for USD 16.5 Billion, Plans Strategic Site Sales to Novo Nordisk
    • 14.3.8. TriLink BioTechnologies and FUJIFILM Toyama Chemical Forge Partnership to Enhance mRNA Drug Development and Manufacturing Efficiency
    • 14.3.9. Ethris Launches First Human Trial of Innovative Inhaled RNA Therapy for Virus-Induced Asthma
    • 14.3.10. Moderna Inc. Advances mRNA Research with New Australian Incubator Network and Vaccine Manufacturing Facility
    • 14.3.11. Bill & Melinda Gates Foundation Invests USD 40 Million in Affordable mRNA Vaccine Manufacturing for Low-Income Nations"
    • 14.3.12. Merck and Moderna Launch Global Phase 3 Trial for Advanced Melanoma Therapy
    • 14.3.13. Applied DNA Sciences Enhances mRNA Manufacturing with Spindle Biotech Acquisition, Aims to Improve Yields and Reduce Costs
    • 14.3.14. Sensible Biotechnologies and Ginkgo Bioworks Forge Strategic Alliance for Revolutionizing mRNA Production
  • 14.4. Strategy Analysis & Recommendation
    • 14.4.1. Pfizer Inc.
    • 14.4.2. Moderna, Inc.
    • 14.4.3. Sanofi SA
    • 14.4.4. Ethris GmbH

Companies Mentioned

  • 1. Acuitas Therapeutics Inc.
  • 2. Arcturus Therapeutics Holdings, Inc.
  • 3. Beam Therapeutics Inc.
  • 4. BioNTech SE
  • 5. Catalent, Inc.
  • 6. CureVac N.V.
  • 7. Daiichi Sankyo Company, Limited
  • 8. Danaher Corporation
  • 9. eTheRNA Immunotherapies NV
  • 10. Ethris GmbH
  • 11. FUJIFILM Holdings Corporation
  • 12. Gritstone bio, Inc.
  • 13. In-Cell-Art
  • 14. Merck KGaA
  • 15. Moderna Inc.
  • 16. Novo Nordisk A/S
  • 17. Pfizer Inc.
  • 18. Precision BioSciences, Inc.
  • 19. Regulus Therapeutics Inc.
  • 20. Sangamo Therapeutics, Inc.
  • 21. Sanofi SA
  • 22. Takara Bio Inc.
  • 23. Telesis Bio Inc.
  • 24. Thermo Fisher Scientific Inc.
  • 25. Tiba Biotech LLC
  • 26. TriLink BioTechnologies by Maravai LifeSciences
  • 27. Verve Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. MRNA PLATFORM MARKET RESEARCH PROCESS
  • FIGURE 2. MRNA PLATFORM MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MRNA PLATFORM MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MRNA PLATFORM MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL MRNA PLATFORM MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL MRNA PLATFORM MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES MRNA PLATFORM MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES MRNA PLATFORM MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. MRNA PLATFORM MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. MRNA PLATFORM MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MRNA PLATFORM MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MRNA PLATFORM MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MRNA PLATFORM MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MRNA PLATFORM MARKET DYNAMICS
  • TABLE 7. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MRNA PLATFORM MARKET SIZE, BY NUCLEOSIDE-MODIFIED MRNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MRNA PLATFORM MARKET SIZE, BY UNMODIFIED MRNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MRNA PLATFORM MARKET SIZE, BY MONOCISTRONIC MRNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MRNA PLATFORM MARKET SIZE, BY POLYCISTRONIC MRNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MRNA PLATFORM MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MRNA PLATFORM MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MRNA PLATFORM MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MRNA PLATFORM MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MRNA PLATFORM MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MRNA PLATFORM MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MRNA PLATFORM MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MRNA PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL MRNA PLATFORM MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTIIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES MRNA PLATFORM MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 234. MRNA PLATFORM MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 235. MRNA PLATFORM MARKET, FPNV POSITIONING MATRIX, 2023